Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12616001043426
ACTRN12616001043426
Completed
未知

High-risk patients with operable breast cancer treated with adjuvant dose-dense sequential chemotherapy. A translational study of investigating biomarkers with prognostic value on disease-free survival and overall survival (HE10/10)

Hellenic Cooperative Oncology Group0 sites1,060 target enrollmentAugust 4, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast CancerCancer - Breast

Overview

Phase
未知
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Hellenic Cooperative Oncology Group
Enrollment
1060
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 4, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Hellenic Cooperative Oncology Group

Eligibility Criteria

Inclusion Criteria

  • •Pre and post menopausal patients with intermediate or high\-risk operable breast cancer as defined by the Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005\. A.Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.J. Senn \& Panel Members, Annals of Oncology 16: 1569–1583, 2005 who received dose\-dense sequential adjuvant chemotherapy.

Exclusion Criteria

  • •Documented residual or metastatic disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancerBreast CancerCancer - Breast
ACTRN12615000161527Hellenic Cooperative Oncology Group1,000
Completed
Phase 3
Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97)
ACTRN12611000506998Hellenic Cooperative Oncology Group600
Completed
Not Applicable
Selection of Breast Cancer Patients with Low-risk Tumors using MR Imaging
NL-OMON36966niversitair Medisch Centrum Utrecht60
Completed
Not Applicable
Prevention of breast cancer in high risk women by monitoring microrna expression in nipple aspirate fluid.breast cancerbreast carcinoma100836241000629110006232
NL-OMON44762niversitair Medisch Centrum Utrecht720
Completed
Not Applicable
High Dose Therapy in Poor-Risk Primary Breast CancerBreast cancerCancerBreast
ISRCTN52623943Amgen Limited (UK)